196.00 +0.08 (0.04%)
After hours: 4:47PM EDT
|Bid||192.86 x 1000|
|Ask||196.98 x 1200|
|Day's Range||192.86 - 198.00|
|52 Week Range||118.50 - 224.64|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||15.04|
|Earnings Date||Jul 30, 2020|
|Forward Dividend & Yield||0.04 (0.02%)|
|Ex-Dividend Date||Mar 09, 2020|
|1y Target Est||239.24|
The global case tally from the coronavirus that causes COVID-19 climbed above 5.5 million on Tuesday, as the World Health Organization warned of the possibility of an immediate “second peak” in infections from the current wave, if countries and local governments ease measures to contain the spread too soon.
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
The coronavirus is taking a toll on mental health. The number of prescriptions for antidepressant, anti-anxiety and anti-insomnia medications filled per week increased 21% between Feb. 16 and March 15, 2020, according to a recent report by Express Scripts, a Cigna-owned (CI) pharmacy benefit manager. The study analyzed prescription claims filled between Jan. 19 and March 15 of this year among a sample of more than 31.5 million commercially-insured individuals, and found that claims peaked during the week ending March 15, when the novel coronavirus that causes COVID-19 was declared a pandemic.
Cigna Corp. affirmed Tuesday its full-year outlook for adjusted profit and revenue, and backed its 2021 earnings-per-share target, as the insurer expect to participate in meetings with investors and analysts in the coming weeks. The company expects 2020 adjusted EPS of $18.00 to $18.60 and revenue of $154 billion to $156 billion, both surrounding the FactSet EPS consensus of $18.43 and revenue consensus of $154.71 billion. For 2021, Cigna expects adjusted EPS of $20.00 to $21.00, compared with the FactSet consensus of $20.44. The stock, which is still inactive in premarket trading, has inched up less than 0.1% over the past three months while the S&P 500 has slipped 5.2%.
Global health service company Cigna Corporation (NYSE:CI) issued the following statement to support efforts made by the Administration and the Centers for Medicare and Medicaid Services (CMS) to offer lower insulin costs for Medicare Part D participants for the 2021 plan year.
Cigna (CI) has added a private messaging application to better serve its members amid COVID-19 breakout.
In response to the COVID-19 pandemic, Cigna is making it simpler and more convenient for its customers to access an expanded suite of virtual support services for mental and emotional health.
Cigna (NYSE: CI) and MultiCare Health System have reached a multi-year agreement that ensures access to quality care for Cigna customers at predictable, affordable rates. It covers MultiCare's hospitals and facilities, including Tacoma General Hospital.
According to Greg Fann and Dave Dillon, fellows of the Society of Actuaries who work directly with insurers to set health insurance premium rates, costs will be up “in the 4-6% range for the individual and small group market.” Yahoo Finance’s Ethan Wolff-Mann joins Seana Smith to discuss.
It is hard to get excited after looking at Cigna's (NYSE:CI) recent performance, when its stock has declined 18% over...
Cigna has taken bold actions throughout the COVID-19 pandemic to make it easier and more affordable for customers to access the care they need to fight the virus and prevent its spread. Today, Cigna is taking another step forward by expanding its digital capabilities to help customers with COVID-19 by providing real-time, personalized support. These new virtual solutions will help rapidly identify and assist Cigna customers who arrive in emergency room settings with COVID-19 symptoms, and support those who are actively recovering at home.
Harvard surgeon and author Atul Gawande will step down as chief executive officer to take on the role of chairman at Haven, the healthcare joint venture of Amazon.com Inc, Berkshire Hathaway Inc and JPMorgan Chase & Co. Chief Operating Officer Mitch Betses will manage day-to-day operations, while Haven looks for a new CEO, the company said.
Despite incredible relevancy toward the novel coronavirus pandemic, UnitedHealth Group (NYSE:UNH) was hardly immune to volatility. At one point, UNH stock was down over 33% for the year.Source: Ken Wolter / Shutterstock.com However, in late March, shares began picking up momentum. It wasn't the only one, with other managed care organizations, such as Anthem (NYSE:ANTM), Cigna (NYSE:CI) and Humana (NYSE:HUM) enjoying similar upside.But can you trust this sector given growing concerns about economic stability?InvestorPlace - Stock Market News, Stock Advice & Trading TipsOn one hand, the case for UNH stock and its peers appears to have fundamental justification. Unlike other crises that we have suffered in the modern era, the novel coronavirus is a black swan event that has impacted all of us to a significant degree. In this manner, it's completely dissimilar to localized events, such as the 9/11 attacks or an incident that only impacts certain people, such as the housing crisis of the mid-2000s. * 7 A-Rated REITs to Buy NowNo, the coronavirus is a microbiological threat from which no one can assume they're safe. Undoubtedly, this caused many consumers to open their eyes toward upgrading their medical care. If enough people do this, it could provide a boost to UNH stock.Furthermore, UnitedHealth delivered an earnings beat for its first quarter with an earnings per share of $3.72. Consensus estimates called for EPS of $3.65. Revenue, though, missed slightly at $64.42 billion, whereas analysts had targeted $64.67 billion.Although a very positive outcome considering the circumstances, we're walking through uncharted territory. Thus, it's not unreasonable to believe UNH stock could suffer more turbulence until we get a hold of the true status of our economy. Here are three other reasons why investors need to be careful with UnitedHealth. UNH Stock Has a Flawed Coronavirus CatalystAlthough I understand why many analysts have a bullish take on managed care companies, I believe that they're exaggerating the positive impact of the coronavirus. Yes, the pandemic has caused people to examine their insurance policy and their overall preparedness. But that doesn't necessarily equate to a mass conversion toward UNH.First, the membership metric missed Wall Street's expectation by 2% in the first quarter. This shortfall likely indicates that the growing number of the unemployed, along with broader fears about economic sustainability have negatively affected UnitedHealth.Second, the coronavirus is a rare, one-off event. The last incident like this to hit the U.S. was the H1N1 pandemic, which infected millions and killed approximately 17,000. But this outbreak happened over a decade ago. Frankly, it's not worth adjusting your insurance policy (especially to a premium policy) to address a situation that occurs so infrequently.Not only that, your chances of getting Covid-19 are very slim. Roughly speaking, there are 328 million people in the U.S. At time of writing, there are 1.26 million total cumulative cases of coronavirus here. Thus, we're talking about a disease that has only impacted less than 0.4% of the population.Don't get me wrong - I'm not minimizing this pandemic. But I just don't see the impetus for UNH stock. Sure, people will forever remember the coronavirus, but I doubt they'll switch or upgrade insurance policies over it. The Pandemic Is a Negative for InsurersAs you know, the rising cost of health care has been a vexing issue for patients along with the electorate. However, not having access to health care is a scarier thought for many folks. That's why for those of us that can afford it, we put up with the escalating costs.If you believe the above bullish argument for UNH stock, then you're assuming the outbreak provides an incentive for UnitedHealth. Clearly, the collective health risk has caused people to examine their coverage with "what if" scenarios. But I don't think an outlier is enough to convince people to pay more money for premium care.Indeed, I look at it from the opposite angle. When the coronavirus broke out in a substantial way and disrupted our health care networks, people were incentivized not to visit the hospital or primary care clinic. With so many sick people and medical professionals often working without adequate protection, you were taking huge risks to subject yourself to that environment.Yet at the same time, you were paying your monthly bills as if nothing happened. This then causes people to examine the extreme cost of paying for protection against an event that might not occur.If anything, I see a catalyst for supplemental insurance companies like Aflac (NYSE:AFL), which covers more common unexpected events, such as a broken limb. Because it's supplemental, people can choose whatever services they wish to enhance their overall coverage profile. But besides that, the concept of a bump up in premium covered care doesn't strike me as plausible in this environment. It's All About the EconomyThe Department of Labor will release its April jobs report today. I don't need to know what the number is to know that it's terrible. On Wednesday, Automatic Data Processing (NASDAQ:ADP) released its employment stats, which showed that the private sector shed more than 20 million jobs.Current projections call for the April jobs report to disclose 22 million employment positions lost. That would mean a decade's worth of jobs have evaporated in a span of weeks. It's a staggering thought.And in this paradigm, it's incredibly difficult to reconcile how UNH stock will thrive. Generally, UnitedHealth plans cost more than other coverage programs. Perhaps the first wave of unemployment numbers didn't impact UNH because they disproportionately affected lower-income workers.But if this economic malaise continues, it's inevitable that higher-wage earners in business services and management roles will get the axe. In my opinion, it's already happening. Either way, the middle class cannot avoid the coronavirus. And that would present huge challenges for UNH stock for which I'm not interested in staking my money.A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * America's 1 Stock Picker Reveals Next 1,000% Winner * 25 Stocks You Should Sell Immediately * 1 Under-the-Radar 5G Stock to Buy Now * The 1 Stock All Retirees Must Own The post 3 Reasons to Think Carefully Before Betting on UnitedHealth appeared first on InvestorPlace.
CVS Health (NYSE:CVS) beat market estimates for sales in its May 6 report but the share fell 5% anyway. The CVS stock price has eked out a 3% gain since its mid-March low, while the S&P 500 index is up 5.1% in the same seven or so weeks.Source: Shutterstock InvestorPlace - Stock Market News, Stock Advice & Trading TipsThat report? Earnings of $2.01 billion, $1.53 per share fell short of estimates for $1.70 a share of earnings. But revenue of $66.75 billion was well ahead of estimates for $62.61 billion.Revenue gains were strongest on the insurance side of the house, the former Aetna. Earnings gains were strongest in what it called the retail and long-term care segment, which includes its in-store clinics.Initial reports had earnings of $1.91 a share, which would have beat even the whisper number. This was adjusted income, including some non-GAAP items related to the Aetna deal and amortization of intangible assets. Is the Aetna Deal Working?CVS Health made itself unique in 2018 by paying $69 billion for Aetna. At the time, Aetna was one of four large health insurers left behind by the growth of United Healthcare (NYSE:UNH).The deal came about after the four laggards were kept from merging with each other by the Obama administration. The other three -- Cigna (NYSE:CI), Anthem (NYSE:ANTM) and Humana (NYSE:HUM) -- remain independent. Only Humana has outperformed UNH over the last two years, but the others have all outperformed CVS. * 7 A-Rated REITs to Buy Now CVS is now larger than UNH in terms of annual revenue, $256 billion to $240 billion, but has less than half of its new rival's net income. The goal has been to deliver managed care through CVS pharmacies and, eventually, better value from insurance operations. That goal has yet to be achieved, although UNH has moved into managed care in recent years, following CVS' lead.For investors, this has given CVS stock a better performance than Walgreens Boots Alliance (NASDAQ:WBA), formerly its drug store doppelganger. Over the last two years CVS shares are down 4%, while Walgreens is down by more than a third. But health insurance, by itself, remains a better business. Pandemic's Front LinesPartly because of the Aetna deal, and partly due to its niche in pharmacy, CVS can afford its 50 cents per share dividend payout during the novel coronavirus pandemic. Its full-year guidance on earnings remains unchanged, at $5.47-$5.60 per share diluted and $7.04-$7.17 per share adjusted.During the first quarter CVS Health saw both higher prescription and in-store revenue, and lower benefit costs. April results show a "new normal" of lower merchandise sales and higher pharmacy sales.Patients are focused on Covid-19 and putting off dealing with other medical problems. CEO Larry Merlo expects the second quarter to represent a "trough" in results. But that's much better than the disaster other retailers are predicting. * 9 Online Retail Stocks Profiting From Social Distancing Analysts are divided on how to look at this. Some warn of mounting costs and a retail collapse, telling growth investors to avoid the stock. Others see a promising technical chart, a stock poised to move higher. Still others see a cheap insurer trading at less than 10 times earnings, half what UNH is selling for. Bottom Line on CVS StockMy own view on CVS stock is that the managed care era it was built for has yet to appear.Health insurers are raking in profits under Trump, and anger at this fueled the rise of Bernie Sanders. His failure to beat Joe Biden for the Democratic nomination, in turn, gave more fuel to the insurers. Biden is considered friendlier to the industry.But within the industry, managed care is the trend. CVS stores and clinics should, over time, give it lower costs for chronic care. Other insurers must pay third parties for this care. That's why I have been recommending CVS for over a year. It's why I finally bought shares for my own retirement account.That investment has delivered a tiny, but real profit, and a dividend yield of 3.3%, easily beating a U.S. government bond. In the present market, which still may be taken down by a second wave of coronavirus infections, that's value worth buying.Dana Blankenhorn has been a financial and technology journalist since 1978. His latest book is Technology's Big Bang: Yesterday, Today and Tomorrow with Moore's Law, essays on technology available at the Amazon Kindle store. Write him at firstname.lastname@example.org or follow him on Twitter at @danablankenhorn. As of this writing he owned shares in CVS. More From InvestorPlace * America's 1 Stock Picker Reveals Next 1,000% Winner * 25 Stocks You Should Sell Immediately * 1 Under-the-Radar 5G Stock to Buy Now * The 1 Stock All Retirees Must Own The post CVS Health Beats Estimates, Market Yawns appeared first on InvestorPlace.
Cigna’s Express Scripts is offering a new prescription drug program that limits costs to consumers, acting as a safety net for millions of newly uninsured individuals. Yahoo Finance’s Anjalee Khemlani joins Seana Smith to discuss.
Cigna Services President Tim Wentworth joins Yahoo Finance’s Brian Sozzi, Alexis Christoforous, and Anjalee Khemlani to discuss what the company is doing to help fight the coronavirus pandemic.
Express Scripts is offering discounted $25 and $75 prescription drug prices to the newly uninsured, a stop-gap measure aimed at Americans who lose their jobs and health insurance due to the coronavirus pandemic. The U.S. pharmacy benefit manager owned by Cigna Corp said the offer included thousands of generic drugs, which would be priced at $25 and branded medications priced at $75. Express said the offer, which is temporary, includes drugs for asthma, diabetes drug, glaucoma, heart disease, migraine, reproductive health, seizures and thyroid conditions.
Cigna today is launching its new COVID-19 Customer Protection Program to further safeguard its customers from unexpected costs for COVID-19 care through "surprise" or "balance" bills from out-of-network health care providers.
Cigna (NYSE: CI) and Banner Health have reached a long-term agreement that ensures Cigna customers will have access to quality care at Banner hospitals at predictable, affordable rates.
The Covid-19 induced recession will be bad news for the health insurer Cigna, Bernstein analyst Lance Wilkes wrote in a note Monday morning.
U.S. hospitals, many past the peak coronavirus crush, are relying on plexiglass dividers, advance testing of patients and limited elevator traffic to convince people, especially those needing urgent care, that the facilities are safe. Hospitals put lucrative elective procedures and other nonessential operations on hold weeks ago as they geared up for the coronavirus onslaught. "We have to convey to the public that we are safe ... and to defer medical care in urgent situations will cause more harm," said Mark Solazzo, chief operating officer at Northwell Health, New York's largest healthcare provider.